focus -WSS

focus

author：entertainment 2025-09-27 16:47:46 - browse：57

Business standing in the middle of a maze near a bag with a dollar sign on it. -- biotech coverage from STAT — Adobe

Over the last year or two, something curious has started occurring in the conference rooms and private Zoom meetings of biotech venture capitalists.

Representatives from pension funds, college endowments, family offices, and other organizations with money to invest have become bolder in their requests, according to interviews with a host of VCs. They’re pushing not only for advantageous terms in a VC firm’s latest fund, but in some cases, have angled for equity in the firm itself. These types of conditions aren’t unheard of, but have become more frequent as venture capitalists have a harder time raising funds, and as outside investors feel empowered to ask for more bang for their buck.

“A lot is changing in venture fundraising right now,” said Nan Li, co-founder and managing partner of Dimension, which launched last January. Outside investors tried to ask for a piece of Dimension, but the new firm had more than enough interest in its first fund and was able to turn down those proposals. Two other young VC firms told STAT they’ve fielded similar requests, and one investment group reported that it had managed to negotiate an equity stake in a VC firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： How generative AI ratchets up security threats for health systems

knowledge

Wikipedia

WSS

10 reasons why health care startups fail

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

How CO2 helps viruses stay alive longer in the air

FTC loses bid to block Novant's North Carolina hospital merger

Bernie Sanders is gearing up to subpoena pharma CEOs

Medicare Advantage insurers face 0.2% cut to 2025 payments

Wikipedia

focus

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

White House pharmacy plagued with problems, investigation finds

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Anthony Fauci pushes back on GOP claims during Covid hearing

Bright Health sells Medicare Advantage business to Molina

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Supreme Court strikes down use of affirmative action

Merck, Johnson & Johnson CEOs will testify on high drug prices

In age of alternative facts, a scholarly course on calling out crap

Philips to halt sales of sleep apnea machines in U.S.

knowledge

Vertex non

Medicare Advantage insurers face 0.2% cut to 2025 payments

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Humana’s losses in Medicare Advantage tank its stock

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Medicare drug price negotiation legal challenge met with skepticism

focus

knowledge

Wikipedia

Wikipedia